Island Pharmaceuticals (ASX: ILA) — Perfil da empresa, notícias e dados financeiros
Island Pharmaceuticals is a clinical-stage antiviral drug development company focused on creating therapeutics for high-impact infectious diseases.
Island Pharmaceuticals
Island Pharmaceuticals is a clinical-stage antiviral drug development company focused on creating therapeutics for high-impact infectious diseases. The company utilizes a drug repurposing strategy to minimize development costs and expedite clinical timelines by advancing molecules with demonstrated human safety profiles. Its research pipeline primarily addresses vector-borne viral infections, such as dengue fever and other mosquito-borne flaviviruses, alongside severe filovirus threats including Ebola and Marburg viruses. By targeting viral replication mechanisms, the company aims to deliver oral small-molecule treatments and broad-spectrum countermeasures for global public health emergencies, military biodefense applications, and unaddressed endemic tropical diseases.
Resumo
Operações
Produtos e/ou serviços de Island Pharmaceuticals
- Dengue and Flavivirus Therapeutics: Clinical-stage oral small molecule antiviral therapeutics targeted at treating dengue fever and secondary mosquito-borne flavivirus infections to reduce systemic viral load, prevent severe clinical complications, and accelerate patient recovery.
- Filovirus and Broad-Spectrum Antivirals: Broad-spectrum nucleoside RNA polymerase inhibitor therapeutics designed to neutralize severe filovirus threats including Ebola and Marburg viruses, alongside more than twenty distinct single-stranded RNA viral pathogens causing global public health emergencies.
- Repurposed Antiviral Drug Development: Differentiated pharmaceutical drug repurposing programs aimed at accelerating clinical development timelines and reducing capital expenditure by repurposing known therapeutic molecules with documented human safety profiles toward urgent unaddressed infectious disease indications.
- Prophylactic Mosquito-Borne Interventions: Preventive oral antiviral treatments intended for short-term administration to protect military personnel, international travelers, and high-risk endemic populations residing in or traveling through regions subject to seasonal vector-borne viral outbreaks.
- Biodefense and Emergency Countermeasures: Medical countermeasure development programs tailored for government defense and public health agencies, seeking effective treatments for lethal hemorrhagic fevers and emerging biological threats to fortify emergency response stockpiles and biosecurity preparedness.
- Priority Review and Monetization Pathways: Regulatory pathway optimization strategies focused on securing priority review vouchers, orphan drug designations, and expedited approval frameworks from international health authorities to accelerate commercial distribution and potential non-dilutive voucher monetization.
equipe executiva do Island Pharmaceuticals
- David Charles FosterMD, CEO & Executive Director
- Cameron Peter JonesCFO & Company Secretary
Últimas notícias sobre a Island Pharmaceuticals
Island Pharmaceuticals secures 7-year US market exclusivity
AustraliaIsland Pharmaceuticals expands US Army partnership for Marburg study
AustraliaIsland Pharmaceuticals advances Galidesivir
AustraliaIsland Pharmaceuticals partners with Burnet Institute for antivirals
AustraliaIsland Pharmaceuticals taps USAMRIID to combat Marburg
AustraliaIsland Pharmaceuticals raises $9M to fast-track pipeline
Australia
Comunicados recentes
O que a Island Pharmaceuticals (ILA) comunicou ao mercado, do mais recente para o mais antigo.
- Notification regarding unquoted securities - ILA
- Galidesivir GMP manufacturing commencesFato relevante
- FDA Grants Orphan Designation for Galidesivir in MarburgFato relevante
- Investor Presentation - Asia Dengue SummitFato relevante
Principais indicadores financeiros
Resultados divulgados pela Island Pharmaceuticals, em AUD.
- Cap. de mercado
- 96,2 mi
- Receita (TTM)
- 282,7 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 282,7 mil | -10,6 mi | -9,8 mi | |
| 118,9 mil | -5,4 mi | -3,9 mi | |
| 1,3 mi | -5,1 mi | -2,9 mi | |
| 11,1 mil | -2,9 mi | -2,8 mi |